Contraceptive options for women in selected circumstances.
Young women under the age of 16 years require special consideration when requesting contraception. Such young women can give voluntary consent, which enables prescription and supply providing that the practitioner has determined that the minor is sufficiently mature to understand the details of the method and its use. All reversible methods may be appropriate but it is necessary to provide information in a form that is fully understood. For women with pre-existing medical conditions including obesity, the benefits and risks of the use of individual methods needs to be weighed against the risks of pregnancy for that woman.
Weisberg
Edith
E
Sydney Centre for Reproductive Health Research, FPNSW, Sydney University, Sydney, NSW 2006, Australia. edithweisberg@bigpond.com
D000293:Adolescent; D000328:Adult; D000740:Anemia; D001941:Breast Diseases; D002318:Cardiovascular Diseases; D017280:Condoms / Q000009:adverse effects; D003267:Contraception / Q000009:adverse effects / Q000379:methods*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects; D000075202:Contraindications; D017135:Desogestrel / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003920:Diabetes Mellitus; D004338:Drug Combinations; D004343:Drug Implants / Q000009:adverse effects / Q000627:therapeutic use; D004827:Epilepsy; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006349:Heart Valve Diseases; D006801:Humans; D006973:Hypertension; D015212:Inflammatory Bowel Diseases; D007267:Injections; D007434:Intrauterine Devices / Q000009:adverse effects; D016912:Levonorgestrel / Q000009:adverse effects / Q000627:therapeutic use; D008107:Liver Diseases; D008180:Lupus Erythematosus, Systemic; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D008881:Migraine Disorders; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D009644:Norgestrel / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D009765:Obesity; D057240:Patient Preference; D011247:Pregnancy; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use; D020521:Stroke; D055815:Young Adult
D003271:Contraceptive Agents, Female; D004338:Drug Combinations; D004343:Drug Implants; C516519:NuvaRing; C511292:Ortho Evra; D011372:Progestins; C044815:etonogestrel; D009644:Norgestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D017135:Desogestrel; D017258:Medroxyprogesterone Acetate; C024319:norethindrone enanthate; D009640:Norethindrone